CClinicalTrials.gg
Sign In
Status unknownNCT05099575Updated Oct 29, 2021

Protocols for Prevention of PPH During CS in High Risk Group

An observational study in Atonic PPH, sponsored by Assiut University. Status unknown. Open to female participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
448
Ages
19 Years to 40 Years
Sex
Female
01

Study summary

PPH is one of the most leading causes of maternal mortality,. It means loss of 500 ml blood after vaginal delivery and 1000 ml blood after cesarean delivery. Although it's preventable it represents about 27%of maternal deaths. Atony is the main cause of PPH. 70%of PPH corresponds to uterine atony. Uterotonics like oxytocin, misoprostol, ergometrine, carbetocin and combinations of these drugs can be used but until now there is no agreement on medication that can be the most effective.

02

Conditions studied

  • Atonic PPH
03

In context

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Prevention of atonic PPH during CD in high risk group

Inclusion criteria

    1. Pregnant full term>37 w 2. Maternal age 19- 40 3.physical state 1\&2 4.patient willing to enter the study

Exclusion criteria

Exclusion Criteria:

  • 1.who refuse to participate in study 2.immunocomprmized and patients who had contraindicated from any of drugs used 3.patients with hypersensitivity to any drug
05

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
448 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pregnant women who receive oxytocin

    Drug: Syntocinon, papal, misotac

  • Pregnant Women who receive carbetocin

    Drug: Syntocinon, papal, misotac

  • Pregnant women who receive misoprostol

    Drug: Syntocinon, papal, misotac

  • Pregnant women who receive ergometrine

    Drug: Syntocinon, papal, misotac

Interventions

  • DrugSyntocinon, papal, misotac

    Using different drugs to prevent atonic PPH during CD in high risk group

06

What researchers measure

Primary outcomes

  1. Amount of blood loss

    Decrease amount of blood loss

    Time frame: 1 year

Secondary outcomes

  1. Finding the drug most effective with least adverse effects

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05099575
Lead sponsor
Assiut University
Responsible party
Randa Wanees Ahmed (Randa Wanees Ahmed, Assiut University) — Principal investigator
First posted
Oct 29, 2021
Start date
Oct 30, 2021 (estimated)
Primary completion
Oct 30, 2022 (estimated)
Completion
Oct 30, 2022 (estimated)
Last update
Oct 29, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Assiut University

Start the discussion